Anzeige
Mehr »
Login
Dienstag, 14.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
862 Leser
Artikel bewerten:
(2)

Makor Group Hires New Vice President For Middle East Operations, Daniel Nevo

Finanznachrichten News

LONDON, Sept. 9, 2020 /PRNewswire/ -- Makor Group ("Makor"), an international Financial services corporation, is pleased to announce the appointment of Mr. Daniel Nevo as the new Vice President of Makor's Investment banking Middle East Operations, based in Tel Aviv. Mr. Nevo will be joining Makor to focus on the Group's continued global expansion, focusing on the development of its Technology & Investment Banking Division.

"With the recent opening of diplomatic and commercial channels between Israel and the UAE, we at Makor are excited to seize the new growth opportunities within the region," said Makor Group founder Michael Halimi. "To that end, I am very pleased to be welcoming Daniel [Nevo] to the Makor family. His extensive political and diplomatic experience within the region will undoubtedly prove itself to be a fantastic asset for the team."

Nevo joins Makor bringing with him decades of diplomatic and foreign affairs experience. As former Ambassador of Israel in Jordan (2009 - 2015), he has been credited with developing the relationship between the two neighboring countries.

Nevo began his career in 1985. Having completed his military service in Israel and graduated from the Hebrew University in Jerusalem with a Bachelor in Jewish History and Geography, he joined the Israeli Ministry of Foreign Affairs. In 1986, he became Adviser to the Israeli diplomatic mission to the United Nations. In 1988, Nevo joined the Israeli Consulate in Sydney, Australia. Through this period, he also boasts experience as a Coordinator for the Refugee Working Group (1993 - 1995) and Coordinator for Multilateral Peace Talks, a post he took up from 1996. In 2000, Nevo moves to Amman, Jordan, to join the Israeli Embassy, where he works in a variety of posts including Charge D'Affaires (2005 - 2006) and Director of Multilateral Peace Talks for Coordination and Water Issues (2007 - 2009), culminating in his appointment as Ambassador.

Notes to editors:

About Makor (www.makor-capital.com)

Makor Group is an FCA-regulated international brokerage firm established in March 2011 by Michael Halimi and Avi Bouhadana, former Co-Heads of Global Equities at Cantor Fitzgerald Europe. Makor provides securities research and execution services to institutional investors across all asset classes.

With offices in New York, Chicago, London, Paris, Geneva, Gibraltar, Tel Aviv and Singapore, and over 150 group employees, Makor provides its clients with an around-the-clock single point of contact. Makor's reputation for original and innovative trading ideas in risk arbitrage, special situations, relative value, and event-driven opportunities is unparalleled. The firm has been widely recognized for its achievements, and for the past 4 years was ranked 1st in the Thomson Reuters EXTEL risk-arb research surveys.

Makor acts as agent-only and is therefore not susceptible to common industry conflicts of interest. The firm takes no proprietary positions and as such acts exclusively in the interests of its clients. Makor's understanding of local markets, and extensive global relationships, generate unique sources of liquidity for a diverse client base across all asset classes.

In addition to strong client relationships, Makor is a trusted partner for global custodians and prime brokers, understanding that both are integral to the smooth and effective execution of all client transactions. A focus on supporting prime brokerage services, including custody and trade settlement, has been essential to the growth and success of the Makor franchise.

Contact Details

Anastasia Ulianova
+1 212 419 4000
aulianova@makorsecurities.com

© 2020 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.